Stem-Cell Wonderland
By Ralph Brave,
Sacramento News & Review
| 10. 20. 2005
Will cures be affordable to all?
Last week, a middle-aged woman from Maryland sat in the Denver airport, reading a story in The New York Times headlined "California Maps Strategy for Its $3 Billion Stem Cell Project." Asked whether she's professionally involved in the life sciences, she said, "No." Why then was she reading this particular article? Without hesitation she replied, "My father died from Parkinson's disease."
So it is around the state, the nation and even the globe: Having launched a major stem-cell venture nearly a year ago, California is being watched and looked to for stem-cell cures for all kinds of chronic diseases and conditions.
But the woman in the airport would not have been encouraged by the tale told in the most recent University of California, Berkeley, alumni magazine of a woman near her own age suffering from Parkinson's. This woman's husband happens to be both a cell biologist and director of Berkeley's stem-cell center. When it comes to the prospect of a stem-cell therapy to save his wife or any other Parkinson's patient, he states his scientific opinion succinctly: "Right now, it's...
Related Articles
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Hannah Thomasy, The Scientist | 03.15.2024
23andMe’s stock price since late 2020
23andMe, the first-off-the-blocks personal genomics company, has been struggling lately. In October, there were reports of a massive data breach focusing on 999,999 people with Ashkenazi heritage. The company eventually admitted that hackers had gained at least some access to 6.9 million profiles, and suggested that this was due to customers who had reused passwords. Even before news of the huge leak and the PR faux pas that followed, the company’s stock had...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...